Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01921114 · ClinicalTrials.gov registry record · NA
The PROOF Study: The PICC Related Obstruction Of Flow Study
A NA study, sponsored by Angiodynamics.
- Terminated
- Registry status
- NA
- Development phase
- 57
- Enrollment target
NCT01921114: Clinical Trial NA study, sponsored by Angiodynamics.
NCT01921114 is a NA study that was terminated before completion, run by Angiodynamics. The registered enrollment target is 57 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01921114, a NA study, was terminated before completion, sponsored by Angiodynamics.
- TERMINATED
- Registry status
- NA
- Development phase
- 57 participants
- Enrollment target
Study Summary
The main purpose of this study is to confirm whether the AngioDynamics BioFlo™ Peripherally Inserted Central Catheter (PICC) is associated with less formation of blood clots compared to another commercially available PICC.
Interventions
- DEVICE BioFlo™ Peripherally Inserted Central Catheter (PICC)
- DEVICE Bard® Dual-Lumen PowerPICC SOLO2®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-08 |
| Phase | NA |
Why NCT01921114 stopped before completion
NCT01921114 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which BioFlo™ Peripherally Inserted Central Catheter (PICC) is the first listed.
NCT01921114 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01921114 about?
NCT01921114 is a clinical study titled "The PROOF Study: The PICC Related Obstruction Of Flow Study". The main purpose of this study is to confirm whether the AngioDynamics BioFlo™ Peripherally Inserted Central Catheter (PICC) is associated with less formation of blood clots compared to another commercially available PICC.
What is the current status of trial NCT01921114?
This trial is currently terminated. It is a NA study. The enrollment target is 57 participants. The study started on 2013-10. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01921114?
The interventions under investigation include: BioFlo™ Peripherally Inserted Central Catheter (PICC) (DEVICE), Bard® Dual-Lumen PowerPICC SOLO2® (DEVICE).
Who is sponsoring clinical trial NCT01921114?
This trial is sponsored by Angiodynamics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01921114's enrollment target sits among peer trials
57 1261st of 2000 higher than 739 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia